# A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Study · id `cardio:ct-nct07241390` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07241390](<https://clinicaltrials.gov/study/NCT07241390>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07241390

Browse, organ or system: Brain; Kidneys  
Browse, condition area: Stroke; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7140 participants.

## Technical summary

Registry record NCT07241390. Randomized; double masking; primary purpose treatment. Start 2025-12-01 (actual); primary completion 2031-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 7140 participants (planned count; ClinicalTrials.gov record NCT07241390, source copy `cardio:ctgov-nct07241390-2026-11-04`, retrieved 2026-11-18)
- Started: 2025-12-01 (actual) (ClinicalTrials.gov record NCT07241390, source copy `cardio:ctgov-nct07241390-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2031-08 (anticipated) (ClinicalTrials.gov record NCT07241390, source copy `cardio:ctgov-nct07241390-2026-11-04`, retrieved 2026-11-18)
- Completion: 2031-08 (anticipated) (ClinicalTrials.gov record NCT07241390, source copy `cardio:ctgov-nct07241390-2026-11-04`, retrieved 2026-11-18)
- Countries: Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Czechia; Estonia; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Philippines; Poland; Romania; Serbia; Slovakia; South Africa; South Korea; Spain; Taiwan; Thailand; Tunisia; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT07241390, source copy `cardio:ctgov-nct07241390-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07241390-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Condition: Atherosclerosis Cardiovascular Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): Orforglipron
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 9a5ffcb7d7ff6fff15763d26d283975d9e75fb75fd1ffaa143547d011d53cfd1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
